Quarterly report pursuant to Section 13 or 15(d)

Disclosure of Correction of Immaterial Error (Summary of Reclassifications) (Details)

v3.22.0.1
Disclosure of Correction of Immaterial Error (Summary of Reclassifications) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Operating expense:        
Cost of goods sold $ 113 $ 211 $ 153 $ 318
Research and Development 3,331 2,374 5,842 4,236
General and administrative 8,362 5,665 14,996 11,030
Total operating expenses 11,693 8,039 20,838 15,266
Eliminations [Member]        
Operating expense:        
Research and Development (431) (301) (908) (519)
General and administrative (93) (225) (153) (455)
Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold   215   269
Research and Development 2,213 373 3,734 608
General and administrative 4,832 2,971 8,316 5,643
Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold 113 (4) 153 49
Research and Development 1,549 2,302 3,016 4,147
General and administrative $ 3,623 2,919 $ 6,833 5,842
Statement of Operations Reclassifications [Member]        
Operating expense:        
Cost of goods sold   211   318
Research and Development   2,374   4,236
General and administrative   5,665   11,030
Total operating expenses   $ 8,250   $ 15,584
Cost of goods sold, % change   100.00%   100.00%
Research and Development, % change   (3.00%)   1.00%
General and administrative, % change   (2.00%)   (3.00%)
Statement of Operations Reclassifications [Member] | As Reported [Member]        
Operating expense:        
Research and Development   $ 2,444   $ 4,206
General and administrative   5,806   11,378
Total operating expenses   8,250   15,584
Statement of Operations Reclassifications [Member] | Reclassification, Adjustment [Member]        
Operating expense:        
Cost of goods sold   211   318
Research and Development   (70)   30
General and administrative   (141)   (348)
Segment Reporting Reclassifications [Member] | As Reported [Member]        
Operating expense:        
Research and Development   2,444   4,206
General and administrative   5,806   11,378
Segment Reporting Reclassifications [Member] | As Reported [Member] | Eliminations [Member]        
Operating expense:        
Research and Development   (301)   (519)
General and administrative   (225)   (455)
Segment Reporting Reclassifications [Member] | As Reported [Member] | Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]        
Operating expense:        
Research and Development   525   867
General and administrative   2,981   5,653
Segment Reporting Reclassifications [Member] | As Reported [Member] | Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]        
Operating expense:        
Research and Development   2,220   3,858
General and administrative   3,050   6,180
Segment Reporting Reclassifications [Member] | Reclassification, Adjustment [Member]        
Operating expense:        
Cost of goods sold   211   318
Research and Development   2,374   4,236
General and administrative   5,665   11,030
Segment Reporting Reclassifications [Member] | Reclassification, Adjustment [Member] | Eliminations [Member]        
Operating expense:        
Research and Development   (301)   (519)
General and administrative   (225)   (455)
Segment Reporting Reclassifications [Member] | Reclassification, Adjustment [Member] | Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold   215   269
Research and Development   373   608
General and administrative   2,971   5,643
Segment Reporting Reclassifications [Member] | Reclassification, Adjustment [Member] | Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]        
Operating expense:        
Cost of goods sold   (4)   49
Research and Development   2,302   4,147
General and administrative   $ 2,919   $ 5,842